Biotech startups, ImmunOs Theraputics and Noema Pharma are developing new therapies addressing solid tumours and Tuberous sclerosis, a complex genetic multisystem disorder, respectively. A new partnership with industry player, Merck, and the conclusion of the enrolment phase brings the startups into the next phase of their development.
ImmunOs Therapeutics AG, a biopharmaceutical company using its HLA-based technology platform to develop first-in-class and innovative therapeutics for the treatment of cancer and autoimmune diseases, has expanded its ongoing Phase I clinical trial of IOS-1002 in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) for the treatment of advanced solid tumours. This is a first-in-human, open-label, non-randomized and multicenter trial designed to assess the safety profile, determine the optimal dosing, and evaluate the antitumor activity of IOS-1002 when used alone and in combination with KEYTRUDA, an established immune checkpoint inhibitor.
IOS-1002 is a novel, multifunctional immunotherapy agent for the treatment of advanced solid tumours that simultaneously targets several immune checkpoints. It is based on a naturally occurring human leukocyte antigen (HLA) targeting LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1. Designed to activate both innate and adaptive immune cells, it modulates the tumour microenvironment, potentially enhancing the effectiveness of existing treatments like KEYTRUDA. By combining these two therapies, ImmunOs Therapeutics aims to improve patient outcomes and expand the therapeutic options for individuals battling advanced solid tumours.
Noema Pharma completes enrolment for Phase 2b study on NOE 101
Based in Basel, Noema Pharma, a clinical-stage biotech company targeting debilitating neuroscience-based disorders with first-in-disease therapeutic approaches. The company has completed the enrolment in the GALENE Phase 2B trial for NOE-TSC-101, or basimglurant, is a potent inhibitor of metabotropic glutamate receptor 5 (mGluR5). It is also currently under clinical investigation for trigeminal neuralgia. The Phase 2B GALENE study (NOE-TSC-201) is a multicenter, 30-week randomized, double-blind, placebo controlled, cross-over study evaluating the efficacy and safety of NOE-101 adjunctive to ongoing antiseizure therapy in patients with uncontrolled seizures associated with TSC. The primary endpoint will assess improvement in seizure frequency for the NOE-101 treatment and placebo treatment periods. Patients who complete the GALENE study may continue to a 52-week open-label extension.
Tuberous sclerosis complex is a rare genetic multisystem disorder caused by mutations in TSC1 and TSC2 genes. This disorder causes uncontrolled benign tumour growth in vital organs of the body including the brain, skin, heart, eyes, kidneys, and lungs and is the leading cause of genetic epilepsy. Approximately 80,000 people in the US and EU are diagnosed with TSC, and about 60 percent of patients do not respond to current treatment options. Their treatment-resistant seizures are often serious or life-threatening.
(Press release/RAN)
0Comments
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
Please login or sign up to comment.
Commenting guidelines